What is the MIRODENAFIL?

MIRODENAFIL is , while it's Molecular Formula is C26H37N5O5S.

What is the CAS number for MIRODENAFIL?

The CAS number of MIRODENAFIL is 862189-95-5.

What is MIRODENAFIL (862189-95-5) used for?

Mirodenafil (Mvix), a second-generation PDE5i, was launched in Korea in November 2007, and its orally dissolving film (Mvix S) was launched in December 2011. The product is available in tablet formulation or orally dissolving film of 50 and 100 mg. Mirodenafil has been approved only in Korea. Its pharmacokinetic profiles include a Tmax of 1.25 h, T1/2 of 2.5 h, and a IC50 for PDE5 of 0.34 nmol/L, which would confer a biochemical property of relatively high affinity (potency) for PDE5. While the pharmacokinetic profile is similar to that of sildenafil, mirodenafil appears to be 10 times more selective for PDE5 than sildenafil.

What is the MIRODENAFIL?

MIRODENAFIL is , while it's Molecular Formula is C26H37N5O5S.

What is the CAS number for MIRODENAFIL?

The CAS number of MIRODENAFIL is 862189-95-5.

What is MIRODENAFIL (862189-95-5) used for?

Mirodenafil (Mvix), a second-generation PDE5i, was launched in Korea in November 2007, and its orally dissolving film (Mvix S) was launched in December 2011. The product is available in tablet formulation or orally dissolving film of 50 and 100 mg. Mirodenafil has been approved only in Korea. Its pharmacokinetic profiles include a Tmax of 1.25 h, T1/2 of 2.5 h, and a IC50 for PDE5 of 0.34 nmol/L, which would confer a biochemical property of relatively high affinity (potency) for PDE5. While the pharmacokinetic profile is similar to that of sildenafil, mirodenafil appears to be 10 times more selective for PDE5 than sildenafil.

Product Class

862189-95-5

Product Name：Mirodenafil
Molecular Formula：C₂₆H₃₇N₅O₅S
Purity：99%
Molecular Weight：531.67

Inquiry

Product Details:

CasNo： 862189-95-5

Molecular Formula： C₂₆H₃₇N₅O₅S

Quality Factory Supply Top Purity Mirodenafil 862189-95-5 Best Price

Molecular Formula:C26H37N5O5S
Molecular Weight:531.67
Boiling Point:730.447 °C at 760 mmHg
PKA:14.96±0.10(Predicted)
Flash Point:395.56 °C
PSA：129.14000
Density:1.339 g/cm³
LogP:3.40800

Mirodenafil(Cas 862189-95-5) Usage

Description	Mirodenafil is a recently developed oral phosphodiesterase type 5 inhibitor (PDE5I) designed for treating erectile dysfunction (ED). As a second-generation PDE5I, it belongs to the drug class that includes well-known medications like avanafil, sildenafil, tadalafil, udenafil, and vardenafil, constituting the primary line of treatment for ED. Mirodenafil exhibits distinctive biochemical features, characterized by a notable affinity for PDE5 and high selectivity for this isoform over others. These properties distinguish it from existing PDE5Is such as sildenafil, vardenafil, and tadalafil, positioning Mirodenafil as a promising candidate for the management of erectile dysfunction.
Consumer Uses	ECHA has no public registered data indicating whether or in which chemical products the substance might be used. ECHA has no public registered data on the routes by which this substance is most likely to be released to the environment.
Factory	Hangzhou Huarong Pharm Co., Ltd. established since 2009 , has been always focusing on supplying products and services to our clients in the field of small molecule drug. Our existing advantages have led to our in-depth services for the R&D of small molecule drug discovery.

862189-95-5 Relevant articles

Efficacy and Safety of Mirodenafil, A New Oral Phosphodiesterase Type 5 Inhibitor, for Treatment of Erectile Dysfunction

Jae‐Seung Paick, MD, PhD, Tai Y. Ahn, MD, PhD, Hyung K. Choi, MD, PhD, Woo‐Sik Chung, MD, PhD, Je J. Kim, MD, PhD, Sae C. Kim, MD, PhD, Sae W. Kim, MD, PhD, Sung W. Lee, MD, PhD, Kweon S. Min, MD, PhD, Ki H. Moon, MD, PhD ...

The Journal of Sexual Medicine, Volume 5, Issue 11, November 2008, Pages 2672–2680

A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, fixed‐dose study was conducted with 223 subjects who were randomized to placebo or mirodenafil at fixed doses of 50 or 100 mg for 12 weeks on an “as needed” basis.

Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats

Young H. Choi, Young S. Lee, Soo H. Bae, Tae K. Kim, Bong-Y. Lee, Myung G. Lee

, Biopharmaceutics & Drug Disposition, Volume30, Issue6 September 2009 Pages 305-317

The pharmacokinetics of mirodenafil and SK3541 were dose-dependent after both intravenous and oral administration of mirodenafil due to the saturable hepatic metabolism of mirodenafil.

Relevant Products

Sparsentan
CAS：254740-64-2
Rivaroxaban intermediate
CAS：446292-08-6
Theophylline Anhydrous
CAS：58-55-9